Contribute to cutting edge gene therapy
Support BioViva’s new dementia study:
Help us meet our $2 million target
The Coalition for Radical Life Extension, a Not-for-Profit 501 (C)(3), is raising money to fund a new study with BioViva. This ethics board approved safety study with efficacy will involve 10 patients and be conducted in Mexico. Cost is approximately $200,000 per patient.
This sponsored, interventional, non-randomized study without a control group will use a novel and proprietary central nervous system gene transfer method to deliver AAV hTert and Klotho genes to patients with mild or moderate dementia, with suspected Alzheimer’s disease.
Inclusion:
50 years of age or above.
Diagnosis of mild to mid stage dementia, with suspected Alzheimer's disease.
Current bloodwork and functional MRI imaging required.
Exclusion:
Active cancer
Psychosis
Liver disease
Pregnancy
As determined by treating physician